secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001213900-26-027890
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay acknowledges NorthStrive's acquisition suggestion, reiterates focus on Symphony platform
--------------------------------------------------------------------------------

- Responds to NorthStrive Fund II LP letter proposing acquisition of Phase-1-ready chronic cough therapeutic program.
- Board and management will evaluate the opportunity but emphasize current priorities: Symphony platform, SYMON II study, FDA submission.
- Notes NorthStrive did not identify the potential counterparty; requests additional diligence information if available.
- Reaffirms commitment to fiduciary duties under Delaware law and preserving cash resources.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026027890/0001213900-26-027890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026027890/ea0281741-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-027890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer